select-d: Anticoagulation therapy in SELECTeD cancer patients at risk of recurrence of venous thromboembolism: a prospective, randomised, open label, multicentre pilot study

Trial Profile

select-d: Anticoagulation therapy in SELECTeD cancer patients at risk of recurrence of venous thromboembolism: a prospective, randomised, open label, multicentre pilot study

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Jan 2017

At a glance

  • Drugs Rivaroxaban (Primary) ; Dalteparin sodium
  • Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
  • Focus Registrational; Therapeutic Use
  • Acronyms select-d
  • Most Recent Events

    • 16 May 2016 Planned End Date changed from 31 Dec 2016 to 31 Dec 2018.
    • 04 Dec 2015 Accural to date is 49% according to the United Kingdom Clinical Research Network Record.
    • 06 Nov 2015 Accural to date is 45% according to the United Kingdom Clinical Research Network Record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top